Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Virios Therapeutics Inc (VIRI)

Virios Therapeutics Inc (VIRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) GlobeNewswire - Mon Oct 7, 6:05AM CDT

VIRI : 0.1550 (+12.40%)
DWTX : 2.34 (+0.86%)
Author
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal MarketBeat - Tue Apr 25, 2023

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia

VIRI : 0.1550 (+12.40%)
AGN : 193.02 (+0.02%)
LLY : 767.76 (+1.35%)
PFE : 26.36 (+2.29%)
GPS : 24.55 (+4.38%)
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase Business Wire - Tue Nov 29, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update Business Wire - Mon Nov 14, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 Business Wire - Thu Nov 3, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics, Inc. Announces Closing of Public Offering Business Wire - Thu Sep 22, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Wall Street - NY Stock Exchange -mHdATQY9fIU-unsplash
Pre-Market Brief: Stocks Mixed Ahead Of FOMC Meeting Barchart - Tue Sep 20, 2022

December S&P 500 futures (ESZ22) are moderately down -0.08% this morning after three major US benchmark indices rebounded from 9-week lows to close higher during the regular session as market participants...

ESZ22 : 3,871.47s (-0.66%)
F : 9.88 (+1.44%)
GM : 51.81 (+2.92%)
VIRI : 0.1550 (+12.40%)
ENVX : 9.73 (+21.17%)
CGNX : 35.77 (-0.83%)
CHNG : 27.49 (+0.26%)
UNH : 500.13 (+2.22%)
Virios Therapeutics, Inc. Announces Pricing of Public Offering Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics, Inc. Announces Proposed Public Offering Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)

Barchart Exclusives

Is It Time to Sell This Second-Fiddle AI Stock Before 2025? Barchart - 59 minutes ago
Bank of America has cut its rating on AMD while lowering its price target. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot